首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1747924

全球德国麻疹疫苗市场

Rubella Vaccines

出版日期: 2025年06月13日 | 出版商:

Global Industry Analysts, Inc. | 英文 275 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球德国麻疹疫苗市场规模将达到 2.211 亿美元

全球德国麻疹疫苗市场规模预计在2024年为1.867亿美元，到2030年将达到2.211亿美元，在2024-2030年的分析期内，复合年增长率为2.9%。单价疫苗是本报告分析的细分市场之一，预计其复合年增长率为4.0%，到分析期结束时规模将达到9,530万美元。麻疹-德国德国麻疹疫苗细分市场在分析期间的复合年增长率预计为1.4%。

美国市场规模估计为 5,090 万美元，而中国市场预计复合年增长率为 5.6%

美国德国麻疹疫苗市场规模预计在2024年达到5,090万美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到4,360万美元，在2024-2030年的分析期内，复合年增长率为5.6%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为1.0%和2.2%。在欧洲，预计德国市场的复合年增长率为1.6%。

全球德国麻疹疫苗市场－主要趋势与驱动因素摘要

为什么德国麻疹疫苗接种仍然是全球公共卫生的重点？

德国麻疹对儿童和成人来说通常是一种轻微的疾病，但孕妇感染风疹会对胎儿构成毁灭性威胁，导致先天性德国麻疹症候群 (CRS)。预防 CRS 最有效的方法是广泛接种德国麻疹疫苗，尤其是麻疹-腮腺炎-德国德国麻疹(MMR) 合併疫苗。虽然全球疫苗接种计划在降低德国麻疹发病率方面取得了显着进展，但仍有差距，特别是在医疗基础设施较弱和疫苗犹豫不决的地区。德国麻疹疫苗接种的重要性不仅在于控制病毒，还在于减少 CRS 导致的长期残疾。由世卫组织和联合国儿童基金会协调的全球宣传活动旨在到 2030 年将德国麻疹纳入全民 MMR 覆盖范围。高所得国家已几乎消灭德国麻疹，但非洲和东南亚部分地区正在透过大规模疫苗接种宣传活动和孕产妇保健计画扩大努力。

联合疫苗和新的物流模式是否扩大了疫苗的可近性？

麻疹、腮腺炎、德国麻疹和德国麻疹德国麻疹（MMR）和德国麻疹混合疫苗（MR）的广泛普及简化了免疫接种程序，并提高了免疫覆盖率。这些多效价疫苗减少了就诊次数，降低了储存需求，并提高了依从性。微针贴片、皮内注射器和耐热製剂等技术创新解决了最后一哩配送的挑战。此外，与全球疫苗和免疫联盟（Gavi）的联合行动为低收入国家提供了MMR补贴和医护人员培训。疫苗储备策略、扩大低温运输和流动医疗团队也改善了偏远社区的推广。这些进展不仅提高了德国麻疹疫苗的覆盖率，而且使其能够更一致地纳入常规免疫接种计划，特别是针对婴儿和青春期女孩。

监测和血清学检测能帮助全球消灭德国麻疹吗？

监测和实验室检测对于检验德国麻疹已消除并确定风险区域至关重要。由数位登记册和实验室网路支援的即时监测系统可以快速发现疫情和慢性呼吸道症候群 (CRS) 病例。血清学调查有助于评估群体免疫力并指南有针对性的疫苗接种活动。日本、英国和韩国等国家已利用全面的监测数据来调整疫苗接种策略，特别是针对儿童时期未接种疫苗的成年男性。监测也有助于随时掌握疫苗的有效性，帮助卫生系统在必要时规划加强接种宣传活动。将德国麻疹监测与麻疹消除计画相协调，可以在通用的公共卫生框架下实现双重病毒控制，从而提供协同途径。

推动整个卫生系统扩大德国麻疹疫苗接种的因素有哪些？

全球风疹疫苗市场的成长受到多种因素的推动，包括全球出生率上升、联合疫苗整合度提升以及公共卫生法规的加强。各国的国家免疫计划，尤其是亚太、非洲和拉丁美洲的国家免疫计划，正在透过常规接种和加强接种两种方式扩大麻疹、腮腺炎、德国麻疹和德国麻疹 (MMR) 疫苗的接种率。新型 MR 疫苗的监管核准和区域性生产措施正在促进疫苗的本地供应并降低成本。国际卫生组织与疫苗製造商之间的战略伙伴关係正在加强供应基础设施。此外，公共卫生讯息讯息和孕产妇筛检计画正在提高医疗保健提供者和育龄妇女对德国麻疹的认识。数位医疗系统正在帮助追踪疫苗接种覆盖率，并发现高风险族群的接种缺口。

部分

按类型（单价製剂、麻疹-德国麻疹疫苗、麻疹/腮腺炎/德国德国麻疹疫苗、麻疹-腮腺炎-德国麻疹-水痘疫苗）；按最终用户（医院、非政府组织、小儿科诊所、其他最终用户）

受访公司范例（值得关注的32家公司）

Abbott Laboratories
AstraZeneca plc
Bavarian Nordic
Bharat Biotech
Biological E. Limited
Cadila Healthcare（Zydus Cadila）
Chumakov Federal Scientific Center
CSL Seqirus
GlaxoSmithKline plc
Haffkine Bio-Pharmaceutical Corporation Ltd.
Indian Immunologicals Limited
Institute of Poliomyelitis and Viral Encephalitides
Merck & Co., Inc.
Panacea Biotec Ltd.
Pfizer Inc.
Sanofi SA
Serum Institute of India Pvt. Ltd.
Sinovac Biotech Ltd.
Takeda Pharmaceutical Company Limited
Wockhardt Ltd.

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口（成品和原始OEM）来预测其竞争地位的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、盈利下降、供应链重组以及其他微观和宏观市场动态。

全球产业分析师密切关注来自全球顶尖首席经济学家（14,949位）、智库（62家）以及贸易和产业协会（171家）的专家的意见，以评估其对生态系统的影响并应对新的市场现实。我们追踪了来自每个主要国家的专家和经济学家对关税及其对本国影响的看法。

全球产业分析师预计，这场动盪将在未来2-3个月内逐渐平息，新的世界秩序将更加清晰地建立。全球产业分析师正在即时追踪这些事态发展。

2025年4月：谈判阶段

在4月的报告中，我们将探讨关税对全球整体市场的影响，并提供区域市场调整。我们的预测是基于历史数据和不断变化的市场影响因素。

2025年7月：最终关税调整

在各国宣布最终重置后，客户将在 7 月收到免费更新，最终更新将包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪了 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业以及各领域专家的最具影响力的首席经济学家，他们共用了这场前所未有的全球经济状况模式转移的影响。我们超过 16,491 份报告大多遵循基于里程碑的两阶段发布计划。

The global market for Rubella Vaccines estimated at US$186.7 Million in the year 2024, is expected to reach US$221.1 Million by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Monovalent Formulation, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$95.3 Million by the end of the analysis period. Growth in the Measles-Rubella Vaccine segment is estimated at 1.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$50.9 Million While China is Forecast to Grow at 5.6% CAGR

The Rubella Vaccines market in the U.S. is estimated at US$50.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$43.6 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global "Rubella Vaccines" Market - Key Trends & Drivers Summarized

Why Does Rubella Vaccination Remain a Public Health Priority Globally?

Rubella, often mild in children and adults, poses a devastating threat to unborn children when pregnant women become infected, leading to congenital rubella syndrome (CRS). The most effective way to prevent CRS is widespread rubella vaccination, particularly through the measles-mumps-rubella (MMR) combined vaccine. Immunization programs have made remarkable progress in reducing rubella incidence globally, yet gaps remain-especially in regions with weak healthcare infrastructure or vaccine hesitancy. The importance of rubella vaccination lies not only in controlling the virus but also in reducing long-term disabilities caused by CRS. Global campaigns coordinated by WHO and UNICEF aim to integrate rubella into universal MMR coverage by 2030. High-income countries have nearly eliminated rubella, while parts of Africa and Southeast Asia are scaling up efforts through mass vaccination campaigns and maternal health programs.

Are Combination Vaccines and New Logistics Models Broadening Access?

The widespread use of MMR and MR (measles-rubella) combination vaccines has simplified immunization schedules and enhanced coverage. These multivalent vaccines reduce clinic visits, cut storage needs, and increase compliance. Innovations like micro-needle patches, intradermal injectors, and thermostable formulations are addressing last-mile delivery challenges. Additionally, collaborative initiatives with Gavi are enabling low-income countries to receive subsidized MMR doses along with training for healthcare workers. Vaccine stockpile strategies, cold chain expansion, and mobile health units are also improving outreach in remote communities. These developments are not only increasing rubella vaccine penetration but also enabling more consistent integration into routine immunization schedules, especially for infants and adolescent girls.

Can Surveillance and Serological Testing Help Eliminate Rubella Globally?

Surveillance and lab testing are critical in verifying rubella elimination and identifying regions at risk. Real-time monitoring systems, supported by digital registries and lab networks, enable prompt detection of outbreaks and CRS cases. Serological surveys help assess population immunity, guiding targeted immunization drives. Countries like Japan, the UK, and South Korea have leveraged comprehensive surveillance data to fine-tune their vaccination strategies, especially for adult men who may have missed childhood immunization. Surveillance also aids in understanding vaccine efficacy over time, helping health systems plan booster campaigns if needed. The harmonization of rubella surveillance with measles elimination programs offers a synergistic pathway to achieving dual viral control under shared public health frameworks.

What’s Powering the Expansion of Rubella Vaccination Across Health Systems?

The growth in the global rubella vaccines market is driven by several factors including rising global birth rates, increasing integration of combination vaccines, and stronger public health mandates. National immunization programs, particularly in Asia-Pacific, Africa, and Latin America, are scaling up MMR/MR vaccine delivery through both routine and supplemental immunization activities. Regulatory approvals of newer MR variants and regional manufacturing initiatives are boosting local availability and reducing costs. Strategic partnerships between international health agencies and vaccine producers are enhancing delivery infrastructure. Moreover, public health messaging and maternal screening programs are increasing rubella awareness among healthcare providers and women of childbearing age. Digital health systems are helping track immunization coverage and flag gaps in high-risk populations, further

SCOPE OF STUDY:

The report analyzes the Rubella Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine, Measles Mumps Rubella Varicella Vaccine); End-Use (Hospitals, NGOs, Pediatric Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

Abbott Laboratories
AstraZeneca plc
Bavarian Nordic
Bharat Biotech
Biological E. Limited
Cadila Healthcare (Zydus Cadila)
Chumakov Federal Scientific Center
CSL Seqirus
GlaxoSmithKline plc
Haffkine Bio-Pharmaceutical Corporation Ltd.
Indian Immunologicals Limited
Institute of Poliomyelitis and Viral Encephalitides
Merck & Co., Inc.
Panacea Biotec Ltd.
Pfizer Inc.
Sanofi S.A.
Serum Institute of India Pvt. Ltd.
Sinovac Biotech Ltd.
Takeda Pharmaceutical Company Limited
Wockhardt Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Rubella Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Global Focus on Eradication of Congenital Rubella Syndrome Drives Vaccination Efforts
- Integration of Rubella with Measles and Mumps Vaccines Expands Market Reach
- WHO and UNICEF Campaigns Propel Coverage in Low- and Middle-Income Countries
- National Immunization Programs Reinforce Market Demand for Rubella-Containing Vaccines
- Increased Availability of Combination Vaccines Simplifies Public Health Deployment
- School Entry Mandates and Routine Immunization Policies Sustain Pediatric Demand
- Improved Cold Chain Infrastructure Supports Widespread Vaccine Distribution
- Rising Seroprevalence Studies Highlight Gaps in Immunity and Drive Catch-Up Campaigns
- Regulatory Approvals for Combination Formulations Enhance Procurement Appeal
- Ongoing Public Health Surveillance Throws the Spotlight on Outbreak Prevention Strategies
- Private Sector Participation in Immunization Clinics Generates Supplemental Demand
- Global Health Goals and SDG Targets Accelerate Government Commitments
- Innovations in Thermostable Vaccines Expand Access in Rural and Remote Regions
- Growing Support for Adolescent and Adult Immunization Policies Expands Demographic Reach
- Donor and NGO Funding Channels Create New Avenues for Market Expansion
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Rubella Vaccines Market Analysis of Annual Sales in US$ for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Rubella Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Monovalent Formulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Monovalent Formulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Monovalent Formulation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Measles-Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Measles-Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Measles-Rubella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Measles / Mumps / Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Measles / Mumps / Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Measles / Mumps / Rubella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Measles Mumps Rubella Varicella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Measles Mumps Rubella Varicella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Measles Mumps Rubella Varicella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for NGOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Pediatric Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Pediatric Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Pediatric Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 29: USA Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 30: USA Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 31: USA 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 32: USA Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 33: USA Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 34: USA 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
CANADA
- TABLE 35: Canada Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 36: Canada Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 37: Canada 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 38: Canada Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 39: Canada Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 40: Canada 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
JAPAN
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 41: Japan Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 42: Japan Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 43: Japan 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 44: Japan Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 45: Japan Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 46: Japan 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
CHINA
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 47: China Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 48: China Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 49: China 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 50: China Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 51: China Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 52: China 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
EUROPE
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 53: Europe Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Rubella Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 55: Europe 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 57: Europe Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 58: Europe 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 59: Europe Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 60: Europe Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 61: Europe 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
FRANCE
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 62: France Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 63: France Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 64: France 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 65: France Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 66: France Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 67: France 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
GERMANY
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 68: Germany Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 69: Germany Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 70: Germany 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 71: Germany Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 72: Germany Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 73: Germany 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
ITALY
- TABLE 74: Italy Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 75: Italy Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 76: Italy 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 77: Italy Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 78: Italy Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 79: Italy 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
UNITED KINGDOM
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 80: UK Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 81: UK Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 82: UK 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 83: UK Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 84: UK Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 85: UK 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
SPAIN
- TABLE 86: Spain Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 87: Spain Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 88: Spain 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 89: Spain Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 90: Spain Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 91: Spain 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
RUSSIA
- TABLE 92: Russia Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 93: Russia Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 94: Russia 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 95: Russia Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 96: Russia Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 97: Russia 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
REST OF EUROPE
- TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 99: Rest of Europe Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 100: Rest of Europe 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 102: Rest of Europe Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 103: Rest of Europe 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
ASIA-PACIFIC
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 105: Asia-Pacific Historic Review for Rubella Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 106: Asia-Pacific 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 108: Asia-Pacific Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 109: Asia-Pacific 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 111: Asia-Pacific Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 112: Asia-Pacific 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
AUSTRALIA
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 113: Australia Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 114: Australia Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 115: Australia 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 116: Australia Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 117: Australia Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 118: Australia 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
INDIA
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 119: India Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 120: India Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 121: India 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 122: India Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 123: India Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 124: India 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
SOUTH KOREA
- TABLE 125: South Korea Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 126: South Korea Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 127: South Korea 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 128: South Korea Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 129: South Korea Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 130: South Korea 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
- TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 132: Rest of Asia-Pacific Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 135: Rest of Asia-Pacific Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
LATIN AMERICA
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 137: Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 138: Latin America Historic Review for Rubella Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 139: Latin America 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 140: Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 141: Latin America Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 142: Latin America 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 143: Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 144: Latin America Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 145: Latin America 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
ARGENTINA
- TABLE 146: Argentina Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 147: Argentina Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 148: Argentina 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 149: Argentina Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 150: Argentina Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 151: Argentina 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
BRAZIL
- TABLE 152: Brazil Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 153: Brazil Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 154: Brazil 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 155: Brazil Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 156: Brazil Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 157: Brazil 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
MEXICO
- TABLE 158: Mexico Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 159: Mexico Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 160: Mexico 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 161: Mexico Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 162: Mexico Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 163: Mexico 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
- TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 165: Rest of Latin America Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 166: Rest of Latin America 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 168: Rest of Latin America Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 169: Rest of Latin America 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
MIDDLE EAST
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 170: Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
- TABLE 171: Middle East Historic Review for Rubella Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 172: Middle East 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 173: Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 174: Middle East Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 175: Middle East 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 176: Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 177: Middle East Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 178: Middle East 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
IRAN
- TABLE 179: Iran Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 180: Iran Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 181: Iran 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 182: Iran Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 183: Iran Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 184: Iran 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
ISRAEL
- TABLE 185: Israel Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 186: Israel Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 187: Israel 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 188: Israel Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 189: Israel Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 190: Israel 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
SAUDI ARABIA
- TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 192: Saudi Arabia Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 193: Saudi Arabia 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 195: Saudi Arabia Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 196: Saudi Arabia 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
- TABLE 197: UAE Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 198: UAE Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 199: UAE 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 200: UAE Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 201: UAE Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 202: UAE 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
- TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 204: Rest of Middle East Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 205: Rest of Middle East 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 207: Rest of Middle East Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 208: Rest of Middle East 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
AFRICA
- Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 209: Africa Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 210: Africa Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 211: Africa 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
- TABLE 212: Africa Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
- TABLE 213: Africa Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
- TABLE 214: Africa 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

02-2729-4219

+886-2-2729-4219

License/价格

全球德国麻疹疫苗市场